Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Jeffrey I. Campbell, Christina Yau, Polina Krass, Dan Moore, Lisa A. Carey, Alfred Au, David Chhieng, Dilip Giri, Chad Livasy, Carolyn Mies, Joseph Rabban, Venetia R. Sarode, Baljit Singh, Laura Esserman, Yunn Yi Chen

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: Several pathologic staging systems characterize residual tumor in patients undergoing neoadjuvant chemotherapy for breast cancer. Pathologic complete response (pCR) is now accepted by the Food and Drug Administration as an endpoint for granting accelerated drug approval. Two other systems of post-neoadjuvant pathologic tumor staging—residual cancer burden (RCB) and the American Joint Committee on Cancer post-neoadjuvant therapy staging system (yAJCC)—have been developed to characterize residual tumors when patients do not achieve pCR. The optimal system and the ways in which these systems complement each other have not been fully determined. Methods: Using data from the I-SPY 1 TRIAL, we compared pCR, RCB, and yAJCC as predictors of early recurrence-free survival (RFS) to identify ways to improve post-neoadjuvant pathologic evaluation. Results: Among 162 patients assessed, pCR identified patients at lowest risk of recurrence, while RCB and yAJCC identified patients at highest risk. Hormone-receptor (HR) and HER2 subtypes further improved risk prediction. Recursive partitioning indicated that triple-negative or HER2+ patients with yAJCC III or RCB 3 have the highest recurrence risk, with an RFS of 27%. Our analysis also highlighted discrepancies between RCB and yAJCC stratification: 31% of patients had discrepant RCB and yAJCC scores. We identified differential treatment of lymph node involvement and tumor cellularity as drivers of these discrepancies. Conclusions: These data indicate that there is benefit to reporting both RCB and yAJCC for patients in order to identify those at highest risk of relapse.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalBreast Cancer Research and Treatment
DOIs
StateAccepted/In press - Jun 2 2017

Fingerprint

Neoplasm Staging
Residual Neoplasm
Breast Neoplasms
Drug Therapy
Recurrence
Neoplasms
Drug Approval
Neoadjuvant Therapy
Survival
United States Food and Drug Administration
Lymph Nodes
Hormones

Keywords

  • Breast neoplasm
  • Cancer staging
  • Disease-free survival
  • Local neoplasm recurrence
  • Lymph nodes
  • Neoadjuvant therapy
  • Pathologic complete response
  • Residual cancer burden
  • Residual neoplasm

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy : results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). / Campbell, Jeffrey I.; Yau, Christina; Krass, Polina; Moore, Dan; Carey, Lisa A.; Au, Alfred; Chhieng, David; Giri, Dilip; Livasy, Chad; Mies, Carolyn; Rabban, Joseph; Sarode, Venetia R.; Singh, Baljit; Esserman, Laura; Chen, Yunn Yi.

In: Breast Cancer Research and Treatment, 02.06.2017, p. 1-11.

Research output: Contribution to journalArticle

Campbell, Jeffrey I. ; Yau, Christina ; Krass, Polina ; Moore, Dan ; Carey, Lisa A. ; Au, Alfred ; Chhieng, David ; Giri, Dilip ; Livasy, Chad ; Mies, Carolyn ; Rabban, Joseph ; Sarode, Venetia R. ; Singh, Baljit ; Esserman, Laura ; Chen, Yunn Yi. / Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy : results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). In: Breast Cancer Research and Treatment. 2017 ; pp. 1-11.
@article{e92bc343674a4449a373968bfa58e759,
title = "Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)",
abstract = "Purpose: Several pathologic staging systems characterize residual tumor in patients undergoing neoadjuvant chemotherapy for breast cancer. Pathologic complete response (pCR) is now accepted by the Food and Drug Administration as an endpoint for granting accelerated drug approval. Two other systems of post-neoadjuvant pathologic tumor staging—residual cancer burden (RCB) and the American Joint Committee on Cancer post-neoadjuvant therapy staging system (yAJCC)—have been developed to characterize residual tumors when patients do not achieve pCR. The optimal system and the ways in which these systems complement each other have not been fully determined. Methods: Using data from the I-SPY 1 TRIAL, we compared pCR, RCB, and yAJCC as predictors of early recurrence-free survival (RFS) to identify ways to improve post-neoadjuvant pathologic evaluation. Results: Among 162 patients assessed, pCR identified patients at lowest risk of recurrence, while RCB and yAJCC identified patients at highest risk. Hormone-receptor (HR) and HER2 subtypes further improved risk prediction. Recursive partitioning indicated that triple-negative or HER2+ patients with yAJCC III or RCB 3 have the highest recurrence risk, with an RFS of 27{\%}. Our analysis also highlighted discrepancies between RCB and yAJCC stratification: 31{\%} of patients had discrepant RCB and yAJCC scores. We identified differential treatment of lymph node involvement and tumor cellularity as drivers of these discrepancies. Conclusions: These data indicate that there is benefit to reporting both RCB and yAJCC for patients in order to identify those at highest risk of relapse.",
keywords = "Breast neoplasm, Cancer staging, Disease-free survival, Local neoplasm recurrence, Lymph nodes, Neoadjuvant therapy, Pathologic complete response, Residual cancer burden, Residual neoplasm",
author = "Campbell, {Jeffrey I.} and Christina Yau and Polina Krass and Dan Moore and Carey, {Lisa A.} and Alfred Au and David Chhieng and Dilip Giri and Chad Livasy and Carolyn Mies and Joseph Rabban and Sarode, {Venetia R.} and Baljit Singh and Laura Esserman and Chen, {Yunn Yi}",
year = "2017",
month = "6",
day = "2",
doi = "10.1007/s10549-017-4303-8",
language = "English (US)",
pages = "1--11",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",

}

TY - JOUR

T1 - Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy

T2 - results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

AU - Campbell, Jeffrey I.

AU - Yau, Christina

AU - Krass, Polina

AU - Moore, Dan

AU - Carey, Lisa A.

AU - Au, Alfred

AU - Chhieng, David

AU - Giri, Dilip

AU - Livasy, Chad

AU - Mies, Carolyn

AU - Rabban, Joseph

AU - Sarode, Venetia R.

AU - Singh, Baljit

AU - Esserman, Laura

AU - Chen, Yunn Yi

PY - 2017/6/2

Y1 - 2017/6/2

N2 - Purpose: Several pathologic staging systems characterize residual tumor in patients undergoing neoadjuvant chemotherapy for breast cancer. Pathologic complete response (pCR) is now accepted by the Food and Drug Administration as an endpoint for granting accelerated drug approval. Two other systems of post-neoadjuvant pathologic tumor staging—residual cancer burden (RCB) and the American Joint Committee on Cancer post-neoadjuvant therapy staging system (yAJCC)—have been developed to characterize residual tumors when patients do not achieve pCR. The optimal system and the ways in which these systems complement each other have not been fully determined. Methods: Using data from the I-SPY 1 TRIAL, we compared pCR, RCB, and yAJCC as predictors of early recurrence-free survival (RFS) to identify ways to improve post-neoadjuvant pathologic evaluation. Results: Among 162 patients assessed, pCR identified patients at lowest risk of recurrence, while RCB and yAJCC identified patients at highest risk. Hormone-receptor (HR) and HER2 subtypes further improved risk prediction. Recursive partitioning indicated that triple-negative or HER2+ patients with yAJCC III or RCB 3 have the highest recurrence risk, with an RFS of 27%. Our analysis also highlighted discrepancies between RCB and yAJCC stratification: 31% of patients had discrepant RCB and yAJCC scores. We identified differential treatment of lymph node involvement and tumor cellularity as drivers of these discrepancies. Conclusions: These data indicate that there is benefit to reporting both RCB and yAJCC for patients in order to identify those at highest risk of relapse.

AB - Purpose: Several pathologic staging systems characterize residual tumor in patients undergoing neoadjuvant chemotherapy for breast cancer. Pathologic complete response (pCR) is now accepted by the Food and Drug Administration as an endpoint for granting accelerated drug approval. Two other systems of post-neoadjuvant pathologic tumor staging—residual cancer burden (RCB) and the American Joint Committee on Cancer post-neoadjuvant therapy staging system (yAJCC)—have been developed to characterize residual tumors when patients do not achieve pCR. The optimal system and the ways in which these systems complement each other have not been fully determined. Methods: Using data from the I-SPY 1 TRIAL, we compared pCR, RCB, and yAJCC as predictors of early recurrence-free survival (RFS) to identify ways to improve post-neoadjuvant pathologic evaluation. Results: Among 162 patients assessed, pCR identified patients at lowest risk of recurrence, while RCB and yAJCC identified patients at highest risk. Hormone-receptor (HR) and HER2 subtypes further improved risk prediction. Recursive partitioning indicated that triple-negative or HER2+ patients with yAJCC III or RCB 3 have the highest recurrence risk, with an RFS of 27%. Our analysis also highlighted discrepancies between RCB and yAJCC stratification: 31% of patients had discrepant RCB and yAJCC scores. We identified differential treatment of lymph node involvement and tumor cellularity as drivers of these discrepancies. Conclusions: These data indicate that there is benefit to reporting both RCB and yAJCC for patients in order to identify those at highest risk of relapse.

KW - Breast neoplasm

KW - Cancer staging

KW - Disease-free survival

KW - Local neoplasm recurrence

KW - Lymph nodes

KW - Neoadjuvant therapy

KW - Pathologic complete response

KW - Residual cancer burden

KW - Residual neoplasm

UR - http://www.scopus.com/inward/record.url?scp=85020074028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020074028&partnerID=8YFLogxK

U2 - 10.1007/s10549-017-4303-8

DO - 10.1007/s10549-017-4303-8

M3 - Article

C2 - 28577078

AN - SCOPUS:85020074028

SP - 1

EP - 11

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

ER -